$6.04
-2.89%
N/A-$0.18
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and ...
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and ...
Pevifoscorvir sodium (formerly ALG-000184) is a clinical-stage oral small molecule classified as a capsid assembly modulator (CAM-E). It is designed to disrupt the assembly of the hepatitis B virus capsid, thereby inhibiting viral replication and potentially reducing the formation of covalently closed circular DNA (cccDNA).
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Limitations of current standard-of-care treatments for chronic HBV that rarely lead to functional cures.
솔루션: Enhanced inhibition of viral replication and potential for improved clinical outcomes in chronic HBV patients.
대상 사용자: Healthcare providers and patients living with chronic HBV infection.
ALG-055009 is a potent and selective thyroid hormone receptor beta (THR-β) agonist, currently in clinical development. By activating this receptor, it aims to reduce hepatic fat accumulation, inflammation, and fibrosis associated with metabolic dysfunction-associated steatohepatitis (MASH).
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Progressive liver damage, fat accumulation, and inflammation in patients with MASH where limited treatment options exist.
솔루션: Reduction of liver fat and inflammation via targeted metabolic pathways.
대상 사용자: Healthcare providers and patients with metabolic liver diseases such as MASH.
ALG-010133 is an oligonucleotide polymer designed to inhibit the secretion of hepatitis B surface antigen (HBsAg) from infected cells, helping to reduce viral load and potentially restore immune function.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: High levels of circulating HBsAg which contributes to chronic HBV persistence and immune exhaustion.
솔루션: Inhibition of HBsAg transport and release to facilitate viral clearance.
대상 사용자: Healthcare providers and patients with chronic HBV.
ALG-020572 is a specialized antisense oligonucleotide targeting the mRNA responsible for the translation of the hepatitis B surface antigen, aiming to lower antigen levels in patients.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: The need for direct suppression of viral protein synthesis in chronic HBV.
솔루션: Suppression of viral surface antigen production at the mRNA level.
대상 사용자: Healthcare providers and patients with chronic HBV.
ALG-125755 is part of Aligos' portfolio of siRNA candidates, leveraging RNA interference technology to selectively knock down the expression of HBV viral products to combat chronic infection.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Persistence of hepatitis B infection due to ongoing expression of viral antigens.
솔루션: Potent silencing of viral gene expression to reduce surface antigen levels.
대상 사용자: Healthcare providers and patients with chronic HBV.
ALG-125097 is an siRNA candidate utilizing RNA interference to inhibit the production of hepatitis B surface antigen, contributing to the broader pipeline of HBV therapies.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Chronic HBV viral load and antigen persistence.
솔루션: RNA-mediated silencing of viral antigen production.
대상 사용자: Healthcare providers and patients with chronic HBV.
ALG-125819 is an investigational siRNA drug candidate intended to reduce the burden of surface antigens in patients infected with the hepatitis B virus.
가격대: N/A (Clinical-stage therapeutic)
페인 포인트: Difficulty in eliminating HBV surface antigen expression.
솔루션: Targeted reduction of viral protein levels via RNA interference.
대상 사용자: Healthcare providers and patients with chronic HBV.